Does the media favor CTKB or ALMR?

In the previous week, Alamar Biosciences had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 3 mentions for Alamar Biosciences and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.34 equaled Alamar Biosciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alamar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CTKB or MRVI?

In the previous week, Cytek Biosciences and Cytek Biosciences both had 2 articles in the media. Cytek Biosciences' average media sentiment score of 0.34 beat Maravai LifeSciences' score of 0.25 indicating that Cytek Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CTKB or BLFS?

In the previous week, Cytek Biosciences had 1 more articles in the media than BioLife Solutions. MarketBeat recorded 2 mentions for Cytek Biosciences and 1 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.67 beat Cytek Biosciences' score of 0.34 indicating that BioLife Solutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioLife Solutions 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CTKB or PSNL?

In the previous week, Personalis had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 3 mentions for Personalis and 2 mentions for Cytek Biosciences. Personalis' average media sentiment score of 1.77 beat Cytek Biosciences' score of 0.34 indicating that Personalis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Personalis 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer CTKB or FTRE?

In the previous week, Fortrea had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 3 mentions for Fortrea and 2 mentions for Cytek Biosciences. Fortrea's average media sentiment score of 0.83 beat Cytek Biosciences' score of 0.34 indicating that Fortrea is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fortrea 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cytek Biosciences (CTKB) Competitors

$5.30 +0.09 (+1.73%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.30 0.00 (-0.09%)

As of 09/18/2026 07:30 PM Eastern

Compare

CTKB vs. ALMR, MRVI, BLFS, PSNL, and FTRE

Should you buy Cytek Biosciences stock or one of its competitors? Cytek Biosciences's main competitors and comparable companies include Alamar Biosciences (ALMR), Maravai LifeSciences (MRVI), BioLife Solutions (BLFS), Personalis (PSNL), and Fortrea (FTRE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Cytek Biosciences compare to Alamar Biosciences?

Cytek Biosciences (NASDAQ:CTKB) and Alamar Biosciences (NASDAQ:ALMR) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

In the previous week, Alamar Biosciences had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 3 mentions for Alamar Biosciences and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.34 equaled Alamar Biosciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alamar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cytek Biosciences currently has a consensus price target of $5.56, indicating a potential upside of 4.95%. Alamar Biosciences has a consensus price target of $31.80, indicating a potential downside of 8.75%. Given Cytek Biosciences' higher possible upside, equities research analysts plainly believe Cytek Biosciences is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

69.5% of Cytek Biosciences shares are held by institutional investors. 10.4% of Cytek Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Alamar Biosciences has lower revenue, but higher earnings than Cytek Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Cytek Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	3.42	-$66.54M	-$0.62	N/A
Alamar Biosciences	$74.21M	32.59	-$29.82M	-$1.96	N/A

Alamar Biosciences has a net margin of 0.00% compared to Cytek Biosciences' net margin of -38.98%. Alamar Biosciences' return on equity of 0.00% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-38.98%	-12.40%	-9.17%
Alamar Biosciences	N/A	N/A	N/A

Summary

Alamar Biosciences beats Cytek Biosciences on 8 of the 14 factors compared between the two stocks.

How does Cytek Biosciences compare to Maravai LifeSciences?

Cytek Biosciences (NASDAQ:CTKB) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

In the previous week, Cytek Biosciences and Cytek Biosciences both had 2 articles in the media. Cytek Biosciences' average media sentiment score of 0.34 beat Maravai LifeSciences' score of 0.25 indicating that Cytek Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 10.4% of Cytek Biosciences shares are owned by insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Cytek Biosciences has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

Cytek Biosciences has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Cytek Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	3.42	-$66.54M	-$0.62	N/A
Maravai LifeSciences	$185.74M	9.74	-$130.77M	-$0.52	N/A

Maravai LifeSciences has a net margin of -37.07% compared to Cytek Biosciences' net margin of -38.98%. Cytek Biosciences' return on equity of -12.40% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-38.98%	-12.40%	-9.17%
Maravai LifeSciences	-37.07%	-15.70%	-8.17%

Cytek Biosciences presently has a consensus price target of $5.56, indicating a potential upside of 4.95%. Maravai LifeSciences has a consensus price target of $6.83, indicating a potential downside of 1.96%. Given Cytek Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cytek Biosciences is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Cytek Biosciences beats Maravai LifeSciences on 11 of the 15 factors compared between the two stocks.

How does Cytek Biosciences compare to BioLife Solutions?

Cytek Biosciences (NASDAQ:CTKB) and BioLife Solutions (NASDAQ:BLFS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

BioLife Solutions has a net margin of 53.29% compared to Cytek Biosciences' net margin of -38.98%. BioLife Solutions' return on equity of 2.70% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-38.98%	-12.40%	-9.17%
BioLife Solutions	53.29%	2.70%	2.49%

In the previous week, Cytek Biosciences had 1 more articles in the media than BioLife Solutions. MarketBeat recorded 2 mentions for Cytek Biosciences and 1 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.67 beat Cytek Biosciences' score of 0.34 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioLife Solutions	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytek Biosciences has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, BioLife Solutions has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market.

69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are owned by institutional investors. 10.4% of Cytek Biosciences shares are owned by insiders. Comparatively, 2.2% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

BioLife Solutions has lower revenue, but higher earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	3.42	-$66.54M	-$0.62	N/A
BioLife Solutions	$106.69M	16.82	-$4.59M	$1.16	31.63

Cytek Biosciences presently has a consensus price target of $5.56, indicating a potential upside of 4.95%. BioLife Solutions has a consensus price target of $31.38, indicating a potential downside of 14.49%. Given Cytek Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cytek Biosciences is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
BioLife Solutions	1 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.18

Summary

BioLife Solutions beats Cytek Biosciences on 11 of the 17 factors compared between the two stocks.

How does Cytek Biosciences compare to Personalis?

Cytek Biosciences (NASDAQ:CTKB) and Personalis (NASDAQ:PSNL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Cytek Biosciences has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Personalis has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market.

In the previous week, Personalis had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 3 mentions for Personalis and 2 mentions for Cytek Biosciences. Personalis' average media sentiment score of 1.77 beat Cytek Biosciences' score of 0.34 indicating that Personalis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Personalis	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Cytek Biosciences has a net margin of -38.98% compared to Personalis' net margin of -153.84%. Cytek Biosciences' return on equity of -12.40% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-38.98%	-12.40%	-9.17%
Personalis	-153.84%	-46.47%	-35.30%

Cytek Biosciences presently has a consensus target price of $5.56, indicating a potential upside of 4.95%. Personalis has a consensus target price of $14.54, indicating a potential downside of 11.37%. Given Cytek Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cytek Biosciences is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Personalis	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

69.5% of Cytek Biosciences shares are held by institutional investors. Comparatively, 61.9% of Personalis shares are held by institutional investors. 10.4% of Cytek Biosciences shares are held by insiders. Comparatively, 4.2% of Personalis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cytek Biosciences has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Cytek Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	3.42	-$66.54M	-$0.62	N/A
Personalis	$69.65M	24.66	-$81.27M	-$1.09	N/A

Summary

Cytek Biosciences beats Personalis on 11 of the 16 factors compared between the two stocks.

How does Cytek Biosciences compare to Fortrea?

Cytek Biosciences (NASDAQ:CTKB) and Fortrea (NASDAQ:FTRE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Cytek Biosciences presently has a consensus target price of $5.56, indicating a potential upside of 4.95%. Fortrea has a consensus target price of $22.00, indicating a potential upside of 10.39%. Given Fortrea's stronger consensus rating and higher probable upside, analysts clearly believe Fortrea is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Fortrea	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36

In the previous week, Fortrea had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 3 mentions for Fortrea and 2 mentions for Cytek Biosciences. Fortrea's average media sentiment score of 0.83 beat Cytek Biosciences' score of 0.34 indicating that Fortrea is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fortrea	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fortrea has a net margin of -3.18% compared to Cytek Biosciences' net margin of -38.98%. Fortrea's return on equity of 10.72% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-38.98%	-12.40%	-9.17%
Fortrea	-3.18%	10.72%	2.17%

Cytek Biosciences has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Cytek Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	3.42	-$66.54M	-$0.62	N/A
Fortrea	$2.72B	0.70	-$986.20M	-$0.91	N/A

69.5% of Cytek Biosciences shares are held by institutional investors. 10.4% of Cytek Biosciences shares are held by insiders. Comparatively, 0.7% of Fortrea shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cytek Biosciences has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Fortrea has a beta of 1.97, meaning that its share price is 97% more volatile than the broader market.

Summary

Fortrea beats Cytek Biosciences on 10 of the 16 factors compared between the two stocks.

Get Cytek Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTKB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTKB vs. The Competition

Export

Metric	Cytek Biosciences	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$677.21M	$10.48B	$7.25B	$13.14B
Dividend Yield	N/A	1.46%	2.57%	12.30%
P/E Ratio	-8.55	70.70	275.79	25.40
Price / Sales	3.42	108.70	695.58	114.44
Price / Cash	N/A	27.34	77.42	51.66
Price / Book	1.99	5.70	10.46	6.33
Net Income	-$66.54M	$56.67B	$3.49B	$358.33M
7 Day Performance	14.97%	4.59%	0.59%	1.12%
1 Month Performance	12.77%	1.52%	-2.01%	-2.67%
1 Year Performance	40.21%	28.13%	18.09%	6.01%

Cytek Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTKB Cytek Biosciences	1.2857 of 5 stars	$5.30 +1.7%	$5.56 +5.0%	+29.6%	$677.21M	$201.49M	N/A	702	News Coverage Gap Down High Trading Volume
ALMR Alamar Biosciences	1.5385 of 5 stars	$28.75 +2.7%	$31.80 +10.6%	N/A	$1.94B	$74.21M	N/A	222
MRVI Maravai LifeSciences	1.2952 of 5 stars	$6.88 +3.0%	$6.83 -0.7%	+142.0%	$1.74B	$185.74M	N/A	415	News Coverage
BLFS BioLife Solutions	2.4694 of 5 stars	$36.39 +2.7%	$31.38 -13.8%	+39.6%	$1.73B	$106.69M	31.37	155
PSNL Personalis	2.1469 of 5 stars	$16.10 -1.2%	$14.54 -9.7%	+181.8%	$1.71B	$69.65M	N/A	260

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTKB) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytek Biosciences (CTKB) Competitors

CTKB vs. ALMR, MRVI, BLFS, PSNL, and FTRE

How does Cytek Biosciences compare to Alamar Biosciences?

Summary

How does Cytek Biosciences compare to Maravai LifeSciences?

Summary

How does Cytek Biosciences compare to BioLife Solutions?

Summary

How does Cytek Biosciences compare to Personalis?

Summary

How does Cytek Biosciences compare to Fortrea?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTKB vs. The Competition

Cytek Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytek Biosciences (CTKB) Competitors

CTKB vs. ALMR, MRVI, BLFS, PSNL, and FTRE

How does Cytek Biosciences compare to Alamar Biosciences?

Does the media favor CTKB or ALMR?

Do analysts rate CTKB or ALMR?

Do institutionals and insiders have more ownership in CTKB or ALMR?

Which has better earnings & valuation, CTKB or ALMR?

Is CTKB or ALMR more profitable?

Summary

How does Cytek Biosciences compare to Maravai LifeSciences?

Does the media favor CTKB or MRVI?

Do insiders & institutionals have more ownership in CTKB or MRVI?

Which has more risk & volatility, CTKB or MRVI?

Which has preferable earnings and valuation, CTKB or MRVI?

Is CTKB or MRVI more profitable?

Do analysts rate CTKB or MRVI?

Summary

How does Cytek Biosciences compare to BioLife Solutions?

Is CTKB or BLFS more profitable?

Does the media prefer CTKB or BLFS?

Which has more risk & volatility, CTKB or BLFS?

Do institutionals & insiders believe in CTKB or BLFS?

Which has better earnings & valuation, CTKB or BLFS?

Do analysts prefer CTKB or BLFS?

Summary

How does Cytek Biosciences compare to Personalis?

Which has more volatility and risk, CTKB or PSNL?

Does the media favor CTKB or PSNL?

Is CTKB or PSNL more profitable?

Do analysts recommend CTKB or PSNL?

Do insiders & institutionals believe in CTKB or PSNL?

Which has preferable valuation and earnings, CTKB or PSNL?

Summary

How does Cytek Biosciences compare to Fortrea?

Do analysts recommend CTKB or FTRE?

Does the media prefer CTKB or FTRE?

Is CTKB or FTRE more profitable?

Which has preferable valuation and earnings, CTKB or FTRE?

Do insiders and institutionals believe in CTKB or FTRE?

Which has more risk & volatility, CTKB or FTRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTKB vs. The Competition

Cytek Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools